Vabysmo’s Lift Off Gives Roche Time For Pipeline Renewal
The company’s new blockbuster eye treatment helped it maintain growth in 2023, while 2024 will see more strategic updates as the company broadens its disease area focus.
The company’s new blockbuster eye treatment helped it maintain growth in 2023, while 2024 will see more strategic updates as the company broadens its disease area focus.